Surpass Evolve Flow Diversion for Embolization of Unruptured Anterior Circulation Aneurysms: 6- and 12-month Obliteration Rates
Document Type
Conference Proceeding - Restricted Access
Publication Date
5-9-2025
Abstract
Flow diversion has emerged as a prominent endovascular technique for the treatment of intracranial aneurysms, offering a less invasive alternative to traditional surgery. The Surpass Evolve flow diverter (FD) aims to enhance operational flexibility and efficacy; however, data on its mid- to long-term outcomes remain limited. This study seeks to address this gap by evaluating the 6- and 12-month occlusion rates in patients with unruptured anterior circulation aneurysms treated with Surpass Evolve FD.
A retrospective analysis of all consecutive patients treated with Surpass Evolve FD between August 2020 and September 2024 at a single tertiary center. Patients with ruptured aneurysms, posterior circulation aneurysms, dissections, or pseudoaneurysms were excluded. All patients have completed or will complete standard 6-month and 12-month follow up angiograms.
Ninety-five patients underwent placement of the Surpass Evolve FD. The mean age was 58.7 (SD 15.0). 86.3% of patients were female and 83.2% of patients have never had previous aneurysm intervention. The mean maximal aneurysm diameter was 6.5 mm (SD 4.1). 61.5% of procedures required post-processing. 84.2% of the patients have had 6-month follow-up angiogram with 60.5% of these showing complete obliteration. 46.3% of the patients have had a 12-month follow up angiogram with 70.5% of these showing complete obliteration, according to the Raymond-Roy occlusion classification.
The Surpass Evolve FD demonstrates favorable 6-month occlusion rates, with further improvements by 12-months. Approximately 60% of devices required post-processing, effectively achieved through single-pass balloon angioplasty or J-wire adjustment. Ongoing angiography and serial MRA surveillance within our cohort will provide further insights into long-term obliteration outcomes.
Recommended Citation
Mitchell M, Verhey L, Sewell A, Mazaris P, Singer J. Surpass evolve flow diversion for embolization of unruptured anterior circulation aneurysms: 6- and 12-month obliteration rates. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1686